Does OSIMERTINIB Cause Lipodystrophy acquired? 6 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 6 reports of Lipodystrophy acquired have been filed in association with OSIMERTINIB (TAGRISSO). This represents 0.0% of all adverse event reports for OSIMERTINIB.
6
Reports of Lipodystrophy acquired with OSIMERTINIB
0.0%
of all OSIMERTINIB reports
0
Deaths
0
Hospitalizations
How Dangerous Is Lipodystrophy acquired From OSIMERTINIB?
Of the 6 reports.
Is Lipodystrophy acquired Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for OSIMERTINIB. However, 6 reports have been filed with the FAERS database.
What Other Side Effects Does OSIMERTINIB Cause?
Death (10,423)
Malignant neoplasm progression (2,920)
Diarrhoea (1,408)
Drug resistance (1,026)
Fatigue (819)
Rash (772)
Decreased appetite (706)
Drug ineffective (627)
Dyspnoea (621)
Nausea (610)
What Other Drugs Cause Lipodystrophy acquired?
LAMIVUDINE (383)
ZIDOVUDINE (313)
NEVIRAPINE (288)
STAVUDINE (283)
RITONAVIR (254)
LOPINAVIR\RITONAVIR (230)
DIDANOSINE (216)
TENOFOVIR DISOPROXIL (205)
EFAVIRENZ (203)
INDINAVIR (195)
Which OSIMERTINIB Alternatives Have Lower Lipodystrophy acquired Risk?
OSIMERTINIB vs OSPEMIFENE
OSIMERTINIB vs OSPHENA
OSIMERTINIB vs OVINE DIGOXIN IMMUNE FAB
OSIMERTINIB vs OXACILLIN
OSIMERTINIB vs OXALIPLATIN